Six Premier Craft Beverage Equipment Suppliers Merge in $100 Million Deal to Launch First-Ever One-Stop-Shop for All Craft Beverage Needs
Lotus Beverage Alliance, a collective of experienced craft beverage equipment manufacturing companies, today announced that it has officially launched as a company. Six leading American craft beverage equipment suppliers have merged in a $100 million deal to create Lotus Beverage Alliance. The combined capabilities of Lotus Beverage Alliance will enable beverage manufacturers of all sizes to access the most comprehensive array of products spanning every step of production for craft beer, wine, hard cider, spirits, cold brew coffee, ready-to-drink cocktails, kombucha, CBD/THC-infused drinks, and sake beverages.
The six merged companies, Alpha Brewing Operations, GW Kent, Twin Monkeys, Stout Tanks and Kettles, Brewmation, and Automated Extractions, are leaders in craft beverage equipment manufacturing and offer essential infrastructure and technology for diversifying the craft beverage industry. The five founders of the six companies will remain in senior leadership positions at Lotus: Matt Rennerfeldt, John Watt, Kevin Weaver, Josh Van Riper, and Randy Reichwage. John Ansbro, an industry veteran with more than 30 years of experience in equipment manufacturing, has been named Chief Executive Officer for Lotus. Ansbro has held senior executive positions at Alfa Laval, Johnson Controls, and the GEA Group.
“Lotus has everything craft beverage creators need to produce the amazing artisanal products they love, for people who love them,” said John Ansbro, CEO of Lotus Beverage Alliance. “Our team’s proven industry experience includes a deep bench of experts helping to optimize the production of handcrafted beverages for consumers to enjoy.”
Lotus Beverage Alliance brings these leading equipment makers under one roof to become the only end-to-end provider dedicated to crafting possibilities for beverage makers, from nationally-distributed beverage purveyors to the everyday craft enthusiast. Lotus Beverage Alliance produces 1,500+ top-shelf products, including turn-key brewhouse production equipment, 304 stainless steel conical fermenters, brew kettles, IBC totes, multi-capacity tanks, mash tuns, brite tanks, canning systems, automation and control systems, packaging, thermal processes and sanitation equipment, raw ingredient supply, parts, and more.
In another industry first, Lotus introduced a proprietary financing program that offers customers affordable financing options, removing cost barriers for startups and smaller beverage producers. Credit approvals typically take less than 24 hours to provide clients with maximum flexibility.
“What a bold vision to pull together such well-respected leaders of each of their respective craft beverage supplier channel segments. The result of this merger for craft beverage makers is sure to be exponential growth and continued beverage innovation,” said Banjo Bandolas, Director of Advertising and Sales at ProBrewer.com. “Lotus appears to be a first-mover by creating a one-stop-shop for craft brewers and companies moving into ‘beyond beer’ products. I look forward to seeing where it evolves.”
Beverage makers who select Lotus Beverage Alliance as their trusted equipment partner can expect:
- Responsive and expert customer service
- A one-stop-shop supply chain for all production needs
- Ready-to-ship production parts and equipment
- High-performance equipment with extended life cycles
- Seamless equipment integration with several third-party brands
- Opportunities for reduced operating costs and downtime through automation
- Greater uptimes and efficiencies in production processes
- Post-purchase technical and operations support
- Proprietary purchase financing program with typical approval in 24 hours
Lotus Beverage Alliance offers extensive support for startups and scale-ups, including:
- Brewing and Distilling
- Quick Ship Equipment and Parts
- Packaging
- Automation and Controls
- Extraction Processing
- Beverage Production Support
Following the six-way merger, the Lotus Beverage Alliance ownership structure includes the founders from all six businesses. Additionally, Lotus has implemented an employee ownership program, at no cost to the employees. Employee ownership has been extended to every single employee throughout the organization. Research has shown that broad-based employee ownership programs improve worker retention, reduce income disparity, and result in higher margins, as well as improved growth and operating efficiencies across various aspects of a business. Lotus collaborated with Ownership Works (https://ownershipworks.org/) in this employee ownership program’s creation. The Lotus merger was facilitated by Ronin Equity Partners, a New York-based investment firm with a long-term growth focus. Ronin is also an investor in Lotus.
Lotus Beverage Alliance will be an exhibitor at the Specialty Coffee Expo in Portland, Oregon, Apr. 21–23, at Booth #456; and at the Craft Brewers Conference in Nashville, Tennessee, May 7-10, 2023 at Booths #500 and #945.
About L otus Beverage Alliance:
Lotus Beverage Alliance is a collective group of experienced companies with extensive knowledge and professional insight into the craft beverage industry. The organization was formed to bring excitement and resources to craft brewing companies by providing an advanced and comprehensive product line, knowledgeable technical guidance, immediate equipment and parts availability, and an excellent customer service team. To learn more about Lotus Beverage Alliance, please visit lotusbevalliance.com. Crafting possibilities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005259/en/
Contact information
For Media Inquiries, Please Contact:
Craft beer media:
Jesse P. Cutler, JP Cutler Media, 415.318.9663, jesse@jpcutlermedia.com
Wine/spirits/specialty beverage media:
Michelle Barry, Chameleon Collective
603.809.2748
LotusBeverage@chameleon.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
